Inamrinone API, formerly known as Amrinone, is a pharmaceutical-grade phosphodiesterase-3 (PDE3) inhibitor with positive inotropic and vasodilatory properties. It is primarily used for the short-term management of congestive heart failure (CHF) in patients who do not respond adequately to conventional therapies.
Inamrinone increases intracellular cyclic AMP (cAMP) levels in cardiac muscle and vascular smooth muscle, improving myocardial contractility while reducing peripheral vascular resistance. It is commonly formulated as an injectable preparation for hospital and critical care settings.
Manufactured under WHO-GMP-certified facilities, our Inamrinone API is produced with advanced quality systems to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive analytical testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Inamrinone API is used in injectable pharmaceutical formulations for the short-term treatment of congestive heart failure and acute cardiac decompensation.
Inamrinone inhibits phosphodiesterase-3 (PDE3), increasing intracellular cAMP levels, enhancing cardiac contractility, and producing vasodilation to improve cardiac output.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Inamrinone API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp